Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04519749 · ClinicalTrials.gov registry record · Phase 1
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
A Phase 1 study of Fabry Disease, sponsored by 4D Molecular Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT04519749 is a Phase 1 study of Fabry Disease that is active but no longer recruiting, run by 4D Molecular Therapeutics. The registered enrollment target is 18 participants, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04519749, a Phase 1 study of Fabry Disease, is active but no longer recruiting, sponsored by 4D Molecular Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.
Conditions Studied
Interventions
- BIOLOGICAL 4D-310
Study Locations (4)
California
- University of California at San Diego - La Jolla
Georgia
- Emory University - Atlanta
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Virginia
- Lysosomal & Rare Disorders Research & Treatment Center, Inc - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2030-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04519749
The ClinicalTrials.gov registry entry for NCT04519749 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (97% lower). The listed sponsor is 4D Molecular Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 1 intervention - of which 4D-310 is the first listed.
NCT04519749 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Georgia, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04519749 about?
NCT04519749 is a clinical study titled "An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease". This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.
What is the current status of trial NCT04519749?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-09-01. Estimated completion is 2030-06.
What conditions does trial NCT04519749 study?
This clinical trial studies the following conditions: Fabry Disease.
What interventions are being tested in trial NCT04519749?
The interventions under investigation include: 4D-310 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04519749?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04519749 being conducted?
This trial has 4 study locations across California, Georgia, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
RECRUITING · Phase 1
-
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
COMPLETED · Phase 1
-
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
-
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
RECRUITING
-
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RECRUITING · Phase 3
-
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.